SCHEMBL144447

SCHEMBL144447

NC[CH]C=Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.59
MAPK1 P28482 2/20 0.50
TRPA1 O75762 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
ALOX5 P09917 1/20 0.50
CYP19A1 P11511 2/20 0.44
MAOA P21397 2/20 0.44
IDO1 P14902 2/20 0.43
GRIN2D O15399 2/20 0.42
GRIN3B O60391 2/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2A Q12879 2/20 0.42
GRIN2B Q13224 2/20 0.42
GRIN2C Q14957 2/20 0.42
GRIN3A Q8TCU5 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9790648 1.00 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL11374373 0.79 MAOB (0.64) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL11374370 0.79 MAOB (0.64) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL1892269 0.77 APP (0.60) MAOBTRPA1ALDH1A1LMNAALOX5
SCHEMBL9427086 0.76 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL28582529 0.76 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL9427090 0.76 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL2563361 0.76 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL4722673 0.76 MAOB (0.59) MAOBMAPK1TRPA1ALDH1A1LMNA
SCHEMBL23458007 0.76 MAOB (1.00) MAOBMAPK1TRPA1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
EP-2431362-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-03-21 EP disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
CN-86102906-A Preparation 1, the method for the two substituted imidazole  salt of 3- 1987-02-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 MAOB 737/4885MAPK1 3241/4885TRPA1 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.